Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.55 |
| ▸ | NOS3 | P29474 | 5/20 | 0.55 |
| ▸ | NOS1 | P29475 | 5/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19506734 | 0.77 | NOS3 (0.39) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL12015758 | 0.77 | NOS2 (0.59) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL7769935 | 0.76 | NOS2 (0.63) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL2717960 | 0.76 | NOS2 (0.57) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL15741417 | 0.75 | — | — | |
| SCHEMBL28303965 | 0.74 | NOS2 (0.55) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL1706050 | 0.74 | NOS2 (0.55) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL2717883 | 0.74 | NOS3 (0.50) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL10264860 | 0.73 | NOS2 (0.65) | NOS2NOS3NOS1HTR1BHTR2B | |
| SCHEMBL28094104 | 0.72 | NOS3 (0.44) | NOS2NOS3NOS1HTR1BHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | NOS2 1075/4885NOS3 1318/4885NOS1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.